LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients

Oncotarget

Volumn 6, Issue 3, 2015, Pages 1569-1581

  Cazzaniga, Valeria ^a   Bugarin, Cristina ^a   Bardini, Michela ^a   Giordan, Marco ^b   te Kronnie, Geertruy ^b   Basso, Giuseppe ^b   Biondi, Andrea ^a   Fazio, Grazia ^a   Cazzaniga, Giovanni ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

BCP ALL; ETV6; LCK; PAX5; STAT5

Indexed keywords

MYC PROTEIN; NINTEDANIB; PROTEIN KINASE LCK; STAT5 PROTEIN; TRANSCRIPTION FACTOR PAX5; PAX5 PROTEIN, HUMAN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETV6;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANIMAL CELL; ARTICLE; CELL CYCLE; CELL PROLIFERATION ASSAY; CELL SURVIVAL; CELL VIABILITY ASSAY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FUSION GENE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; KARYOTYPE; MALE; MOUSE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NONHUMAN; PAX5 GENE; PRESCHOOL CHILD; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION PROFILING; GENETICS; INFANT; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; XENOGRAFT;

ADOLESCENT; ANIMALS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; INFANT; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MALE; MICE; MICE, INBRED NOD; MICE, SCID; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84922703497     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2807     Document Type: Article

References (36)

1. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nature Immunology. 2007; 8:463-470.
2. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446:758-764.
3. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. The New England journal of medicine. 2004; 350:1535-1548.
4. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, Strehl S. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia. 2009; 23:134-143.
5. Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, Bousquet M, Mugneret F, Talmant P, Pages MP, Lefebvre C, Penther D, Lippert E, et al. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood. 2010; 115:3089-3097.
6. Strehl S, Konig M, Dworzak MN, Kalwak K, Haas OA. PAX5/ETV6 fusion defines cytogenetic entity dic(9,12) (p13;p13). Leukemia. 2003; 17:1121-1123.
7. Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, Kearney L, Biondi A. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res. 2001; 61:4666-4670.
8. An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Hall AG, Harrison CJ, Irving JA, et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci U S A. 2008; 105:17050-17054.
9. Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol. 2005; 15:162-174.
10. Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res. 2008; 68:181-189.
11. Fazio G, Cazzaniga V, Palmi C, Galbiati M, Giordan M, te Kronnie G, Rolink A, Biondi A, Cazzaniga G. PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5. Leukemia. 2013; 27:992-995.
12. Accordi B, Espina V, Giordan M, VanMeter A, Milani G, Galla L, Ruzzene M, Sciro M, Trentin L, De Maria R, te Kronnie G, Petricoin E, Liotta L, et al. Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. PLoS One. 2010; 5:e13552.
13. Spijkers-Hagelstein JA, Mimoso Pinhancos S, Schneider P, Pieters R, Stam RW. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLLrearranged infant acute lymphoblastic leukemia. Leukemia. 2013; 27:1063-1071.
14. Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ. 2010; 17:1381-1391.
15. Talab F, Allen JC, Thompson V, Lin K, Slupsky JR. LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells. Mol Cancer Res. 2013; 11:541-554.
16. De Keersmaecker K, Porcu M, Cox L, Girardi T, Vandepoel R, de Beeck JO, Gielen O, Mentens N, Bennett KL, Hantschel O. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica. 2014; 99:85-93.
17. Shi M, Cooper JC, Yu CL. A constitutively active Lck kinase promotes cell proliferation and resistance to apoptosis through signal transducer and activator of transcription 5b activation. Mol Cancer Res. 2006; 4:39-45.
18. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity. 2006; 24:269-281.
19. Filipp D, Ballek O, Manning J. Lck, membrane microdomains, and TCR triggering machinery: defining new rules of engagement. Frontiers in Immunology. 2012; 3:1-14.
20. Fazio G, Daniele G, Cazzaniga V, Impera L, Severgnini M, Iacobucci I, Galbiati M, Leszl A, Cifola I, De Bellis G, Bresciani P, Martinelli G, Basso G, Biondi A, Storlazzi CT, Cazzaniga G. Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2014 Oct 10.
21. Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol. 2009; 9:195-205.
22. Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jack HM, Hurtz C, et al. BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med. 2010; 207:1209-1221.
23. Fortschegger K, Anderl S, Denk D, Strehl S. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development. Mol Cancer Res. 2014; 12:595-606.
24. Yu CL, Jove R, Burakoff SJ. Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol. 1997; 159:5206-5210.
25. Ilaria RL Jr, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996; 271:31704-31710.
26. Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med. 2009; 206:1739-1753.
27. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med. 2010; 2:98-110.
28. Heltemes-Harris LM, Willette MJ, Vang KB, Farrar MA. The role of STAT5 in the development, function, and transformation of B and T lymphocytes. Ann N Y Acad Sci. 2011; 1217:18-31.
29. Lord JD, McIntosh BC, Greenberg PD, Nelson BH. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol. 2000; 164:2533-2541.
30. Jimenez-Velasco A, Roman-Gomez J, Agirre X, Barrios M, Navarro G, Vazquez I, Prosper F, Torres A, Heiniger A. Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia. 2005; 19:2347-2350.
31. Salvador JM, Brown-Clay JD, Fornace AJ Jr. Gadd45 in stress signaling, cell cycle control, and apoptosis. Adv Exp Med Biol. 2013; 793:1-19.
32. Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, Thomas DA, Koeuth T, Baechler EC, Kornblau SM, Farrar MA. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med. 2011; 208:1135-1149.
33. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, Van Zutven LJ, Beverloo HB, Van der Spek PJ, Escherich G, Horstmann MA, Janka-Schaub GE, Kamps WA, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009; 10:125-134.
34. Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia. 2010; 24:896-900.
35. Lin YL, Roux B. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases. J Am Chem Soc. 2013; 135:14741-14753.
36. Livak K, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.